How big is the amyloidosis treatment market?

The market size of the amyloidosis treatment is estimated at USD 6.99 billion in 2027.

How is the amyloidosis treatment industry projected to perform over the next decade?

Amyloidosis Treatment Market size was worth USD 6.6 billion in 2026 and is expected to grow at a 7.03% CAGR between 2027 and 2036, crossing USD 13.02 billion by 2036.

How are disease-modifying therapies reshaping treatment adoption in the amyloidosis treatment market?

Targeted therapies that address disease mechanisms are influencing clinical decision-making by supporting earlier intervention, specialist referrals, and greater demand for treatments linked to controlling disease progression.

How are specialized care networks improving growth opportunities in the amyloidosis treatment market?

Multidisciplinary amyloidosis centers are strengthening diagnosis, treatment coordination, and long-term management, helping identify more patients and improve consistent therapy utilization.

Why do hospitals and clinics hold the largest share of the amyloidosis treatment market?

Hospitals & Clinics held a 52.33% share in 2026 due to their ability to provide coordinated diagnosis, specialist oversight, infusion-based therapies, and multidisciplinary management for complex amyloidosis care.

Why is transplantation the fastest-growing treatment segment in the amyloidosis treatment market?

Transplantation is growing fastest as specialized centers expand capabilities and pursue more intensive treatment approaches for carefully selected patients, supporting stronger long-term disease management outcomes.

Why is North America the leading amyloidosis treatment market?

North America held a 41.72% share in 2026, supported by established diagnostic pathways, broad specialist care access, and coordinated referral networks that enable earlier treatment adoption.

What is driving amyloidosis treatment market growth in Asia Pacific?

Asia Pacific is projected to grow at an 8.48% CAGR as rare disease awareness improves, specialty care expands, and greater diagnosis and treatment access increase therapy adoption across the region.

Who are the major participants shaping the amyloidosis treatment landscape?

Top companies in the amyloidosis treatment market include Pfizer Inc. (United States), Johnson & Johnson (United States), Takeda Pharmaceutical Company Limited (Japan), Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi S.A. (France), Alnylam Pharmaceuticals, Inc. (United States), Amgen Inc. (United States), GlaxoSmithKline plc (United Kingdom).